Explore below for a different way to receive treatment with OPDIVO Qvantig under-the-skin injections (subcutaneous injection).

Potential OPDIVO® (nivolumab) user enjoying a cup of coffee outside with her partner.

Getting treatment for
bladder or urinary tract
cancer (urothelial)

See how you may receive treatment as an intravenous (IV) infusion with OPDIVO or under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig

Actor portrayals.

Bladder or urinary tract cancer after surgery

OPDIVO

For certain adults who have cancer in the bladder or urinary tract removed by surgery to help prevent it from coming back (adjuvant)

OPDIVO Qvantig

For certain adults who have cancer in the bladder or urinary tract removed by surgery to help prevent it from coming back (adjuvant)

Advanced cancer in the bladder or urinary tract

OPDIVO with chemotherapy

For certain adults with previously untreated bladder or urinary tract cancer that has spread or cannot be removed by surgery

OPDIVO Qvantig with chemotherapy

For certain adults with previously untreated bladder or urinary tract cancer that has spread or cannot be removed by surgery

Previously treated advanced bladder or urinary tract cancer

OPDIVO

For certain adults with cancer in the bladder or urinary tract when it has spread and you have received prior treatment*, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with prior treatment*, either before or after surgery to remove your cancer

OPDIVO Qvantig

For certain adults with cancer in the bladder or urinary tract when it has spread and you have received prior treatment*, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with prior treatment*, either before or after surgery to remove your cancer

*Chemotherapy that contains platinum

Hands perusing OPDIVO® (nivolumab) patient resources.

Helpful patient resources

Explore resources to help you along your treatment journey

Clinical trial results for OPDIVO® (nivolumab) and OPDIVO-based combinations.

Clinical trial results

Explore findings from clinical trials with OPDIVO and OPDIVO based combinations



466-US-2600092 04/26